Brief: AB Science: Confirmatory Phase 3 Study AB12005 With Masitinib In First Line Pancreatic Cancer With Pain Was Successful
04/12/2020 07:25
Dec 4 (Reuters) - AB Science SA ABS.PA :
* REG-AB SCIENCE ANNOUNCES THAT CONFIRMATORY PHASE 3 STUDY
AB12005
WITH MASITINIB IN FIRST LINE PANCREATIC CANCER WITH PAIN WAS
SUCCESSFUL
* STUDY WAS SUCCESSFUL IF ITS PRIMARY OBJECTIVE TO TEST A
SIGNIFICANT INCREASE IN OVERALL SURVIVAL WAS REACHED AT A 2.5%
LEVEL OF STATISTICAL SIGNIFICANCE IN EITHER OVERALL POPULATION
WITH PAIN OR IN POPULATION WITH UNRESECTABLE LOCALLY ADVANCED
TUMORS WITH PAIN
Source text for Eikon: ID:nGNE30fxx1
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease